-
公开(公告)号：US20110217311A1
公开(公告)日：2011-09-08
申请号：US13034855
申请日：2011-02-25
申请人： Thorsten LEHMANN-LINTZ , Armin HECKEL , Joerg KLEY , Elke LANGKOPF , Nobert REDEMANN , Achim SAUER , Leo THOMAS , Dieter WIEDENMAYER , Matthias AUSTEN , John DANILEWICZ , Martin SCHNEIDER , Kay SCHREITER , Phillip BLACK , Wesley BLACKABY , Ian LINNEY
发明人： Thorsten LEHMANN-LINTZ , Armin HECKEL , Joerg KLEY , Elke LANGKOPF , Nobert REDEMANN , Achim SAUER , Leo THOMAS , Dieter WIEDENMAYER , Matthias AUSTEN , John DANILEWICZ , Martin SCHNEIDER , Kay SCHREITER , Phillip BLACK , Wesley BLACKABY , Ian LINNEY
IPC分类号： A61K39/395 , C07D495/04 , A61K31/519 , C07D413/14 , A61K31/5377 , A61K31/496 , A61K31/397 , A61K31/575 , A61K31/573 , A61P3/00 , A61P9/00 , A61P29/00
CPC分类号： C07D495/04
摘要： The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
摘要翻译： 本发明涉及包含这些化合物的通式药物组合物的新型噻吩并嘧啶化合物及其用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b的激酶活性）的疾病的治疗用途 ）和/或其变体。
-
公开(公告)号：US20130143892A1
公开(公告)日：2013-06-06
申请号：US13489557
申请日：2012-06-06
申请人： Armin HECKEL , Frank HIMMELSBACH , Elke LANGKOPF , Bernd NOSSE , Neil J. ASHWEEK , Nicole HARRIOTT
发明人： Armin HECKEL , Frank HIMMELSBACH , Elke LANGKOPF , Bernd NOSSE , Neil J. ASHWEEK , Nicole HARRIOTT
IPC分类号： C07D413/14 , C07D403/12 , C07D413/12 , C07D403/14
CPC分类号： C07D413/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/12 , Y10S514/866 , Y10S514/909
摘要： The present invention relates to compounds of general formula I, wherein R1, LP, HetAr, Ar, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
摘要翻译： 本发明涉及通式Ⅰ化合物，其中R1，LP，HetAr，Ar和n如申请中所定义，其具有有价值的药理学性质，特别是与GPR119受体结合并调节其活性。
-
公开(公告)号：US20130065906A1
公开(公告)日：2013-03-14
申请号：US13418376
申请日：2012-03-13
申请人： Bernd NOSSE , Andreas BLUM , Steffen BREITFELDER , Armin HECKEL , Frank HIMMELSBACH , Elke LANGKOPF , Bernd WELLENZOHN , Neil J. ASHWEEK , Nicole HARRIOTT
发明人： Bernd NOSSE , Andreas BLUM , Steffen BREITFELDER , Armin HECKEL , Frank HIMMELSBACH , Elke LANGKOPF , Bernd WELLENZOHN , Neil J. ASHWEEK , Nicole HARRIOTT
IPC分类号： C07D413/14 , A61K31/4545 , C07D417/14 , A61K31/506 , A61P3/06 , A61K31/497 , A61K31/501 , C07D401/14 , A61P3/10 , A61P3/04 , A61K31/454 , C07D413/04
CPC分类号： C07D413/14 , C07D413/04 , C07D417/14
摘要： The present invention relates to compounds of general formula I, wherein the groups R1, LP, LQ, Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
摘要翻译： 本发明涉及通式I的化合物，其中R1，LP，LQ，Ar，m和n基团如本申请中所定义，其具有有价值的药理学性质，特别是与GPR119受体结合并调节其活性 。
-
4.发明申请IMIDAZOLES AND TRIAZOLES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS 有权咪唑和三唑，其制备及其作为药物组合物的用途公开(公告)号：US20080312243A1
公开(公告)日：2008-12-18
申请号：US12192589
申请日：2008-08-15
IPC分类号： A61K31/4439 , A61K31/498 , A61P3/10
CPC分类号： C07D471/04 , C07D249/14 , C07D401/04 , C07D401/12 , C07D401/14
摘要： The present invention relates to imidazoles and triazoles of general formula wherein R1 to R4 and X are defined as in claims 1 to 8, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
摘要翻译： 本发明涉及通式的咪唑和三唑，其中R 1至R 4和X如权利要求1至8中所定义，互变异构体，对映异构体，非对映异构体，其混合物及其盐具有有价值的药理学性质，特别是 对二肽基肽酶-IV（DPP-IV）的活性具有抑制作用。
-
![2-AMINO-IMIDAZO[4,5-D]PYRIDAZIN-4-ONES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS](/abs-image/US/2009/04/02/US20090088569A1/abs.jpg.150x150.jpg)
5.发明申请2-AMINO-IMIDAZO[4,5-D]PYRIDAZIN-4-ONES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS 审中-公开2-氨基咪唑并[4,5-D]吡啶-4-酮，其制备方法及其作为药物组合物的用途公开(公告)号：US20090088569A1
公开(公告)日：2009-04-02
申请号：US12328902
申请日：2008-12-05
申请人： Matthias ECKHARDT , Frank HIMMELSBACH , Elke LANGKOPF , Norbert HAUEL , Mohammad TADAYYON , Leo THOMAS
发明人： Matthias ECKHARDT , Frank HIMMELSBACH , Elke LANGKOPF , Norbert HAUEL , Mohammad TADAYYON , Leo THOMAS
IPC分类号： C07D487/04 , C07D471/04
CPC分类号： C07D487/04 , C07D471/04
摘要： The present invention relates to 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones of general formula wherein R1 to R4 and X are defined as in claims 1 to 6, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
摘要翻译： 本发明涉及以下通式的2-氨基 - 咪唑并[4,5-d]哒嗪-4-酮和2-氨基 - 咪唑并[4,5-c]吡啶-4-酮，其中R1至R4和X为 如权利要求1至6中定义的互变异构体，对映异构体，非对映体，其混合物及其盐，其具有有价值的药理学性质，特别是对二肽基肽酶-IV（DPP-IV）的活性的抑制作用。
-
![8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS](/abs-image/US/2009/05/28/US20090137801A1/abs.jpg.150x150.jpg)
6.发明申请8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS 有权8- [3-氨基哌啶-1-基] - 辛糖，其制备及其作为药物组合物的用途公开(公告)号：US20090137801A1
公开(公告)日：2009-05-28
申请号：US12360392
申请日：2009-01-27
IPC分类号： C07D473/04
CPC分类号： C07D473/04
摘要： Disclosed are substituted xanthines of the formula wherein R is defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
摘要翻译： 公开了下式的取代黄嘌呤：其中R如权利要求1所定义，互变异构体，立体异构体，其混合物及其盐具有有价值的药理学性质，特别是对二肽基肽酶-IV酶活性的抑制作用 DPP-IV）。
-
7.发明申请BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM 有权双相异构体，含有这些化合物的药物组合物，其制备方法及其制备方法公开(公告)号：US20120329778A1
公开(公告)日：2012-12-27
申请号：US13603476
申请日：2012-09-05
申请人： Frank HIMMELSBACH , Elke LANGKOPF , Thomas METZ , Flavio SOLCA , Birgit JUNG , Anke BAUM
发明人： Frank HIMMELSBACH , Elke LANGKOPF , Thomas METZ , Flavio SOLCA , Birgit JUNG , Anke BAUM
IPC分类号： A61K31/517 , C07D403/12 , C07D413/12 , C07D417/12 , C07D239/94 , C07D405/12 , C07D405/14 , A61K31/551 , A61K31/5377 , A61K31/541 , A61P35/00 , A61P11/00 , A61P1/00 , A61P1/16 , C07D401/12
CPC分类号： C07D405/12 , C07D215/42 , C07D215/54 , C07D239/94 , C07D401/12
摘要： The present invention relates to bicyclic heterocycles of general formula wherein Ra to Rc, A to E and X are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
摘要翻译： 本发明涉及通式的双环杂环，其中R a至R c，A至E和X如权利要求1中所定义，互变异构体，立体异构体和盐，特别是其与无机或有机酸或碱的生理上可接受的盐，其具有 特别是对由酪氨酸激酶介导的信号转导的抑制作用，它们在治疗疾病尤其是肿瘤疾病和肺和气道疾病中的应用及其制备。
-
8.发明申请Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 审中-公开黄嘌呤衍生物，其制备及其作为药物组合物的用途公开(公告)号：US20100204250A1
公开(公告)日：2010-08-12
申请号：US12767855
申请日：2010-04-27
申请人： Frank HIMMELSBACH , Michael MARK , Matthias ECKHARDT , Elke LANGKOPF , Roland MAIER , Ralf LOTZ
发明人： Frank HIMMELSBACH , Michael MARK , Matthias ECKHARDT , Elke LANGKOPF , Roland MAIER , Ralf LOTZ
IPC分类号： A61K31/522 , C07D473/28 , A61P3/04 , A61P3/08
CPC分类号： C07D473/08 , C07D473/04 , C07D473/06 , C07D473/10 , C07D473/12
摘要： The present invention relates to substituted xanthines of general formula wherein R1 to R4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
摘要翻译： 本发明涉及通式为其中R1至R4如本文所定义的取代黄嘌呤，其互变异构体及其立体异构体，其混合物，其前体药物及其盐具有有价值的药理学性质，特别是对 酶二肽肽酶-IV（DPP-IV）。
-
公开(公告)号：US20130252937A1
公开(公告)日：2013-09-26
申请号：US13803237
申请日：2013-03-14
申请人： Matthias ECKHARDT , Sara FRATTINI , Dieter HAMPRECHT , Frank HIMMELSBACH , Elke LANGKOPF , Iain LINGARD , Stefan PETERS , Holger WAGNER
发明人： Matthias ECKHARDT , Sara FRATTINI , Dieter HAMPRECHT , Frank HIMMELSBACH , Elke LANGKOPF , Iain LINGARD , Stefan PETERS , Holger WAGNER
IPC分类号： C07D405/12 , A61K31/343 , C07D307/80 , A61K31/351 , A61K31/506 , C07D413/12 , A61K31/422 , A61K31/4155 , A61K31/443 , A61K31/397 , C07D409/12 , A61K31/382 , C07D417/12 , A61K31/427 , A61K31/541 , A61K31/4025 , A61K31/4196 , A61K31/513 , A61K31/501 , A61K31/41 , C07D405/14 , A61K31/497 , C07D413/14 , A61K31/553 , A61K31/5377 , A61K31/4178 , A61K31/4245 , A61K45/06 , C07D407/12
CPC分类号： C07D405/12 , A61K31/343 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/443 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K45/06 , C07D307/80 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
摘要翻译： 本发明涉及通式I的化合物，其中R1，R2和m基团如权利要求1中所定义，其具有有价值的药理学性质，特别是与GPR40受体结合并调节其活性。 该化合物适用于治疗和预防可受该受体影响的疾病，如代谢疾病，特别是2型糖尿病。
-
10.发明申请Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 审中-公开黄嘌呤衍生物，其制备及其作为药物组合物的用途公开(公告)号：US20120252783A1
公开(公告)日：2012-10-04
申请号：US13523939
申请日：2012-06-15
申请人： Frank HIMMELSBACH , Michael MARK , Matthias ECKHARDT , Elke LANGKOPF , Roland MAIER , Ralf LOTZ
发明人： Frank HIMMELSBACH , Michael MARK , Matthias ECKHARDT , Elke LANGKOPF , Roland MAIER , Ralf LOTZ
IPC分类号： A61K31/522 , A61K31/55 , A61P3/10 , A61K31/5377 , A61P3/04 , C07D473/08 , C07D473/06
CPC分类号： C07D473/08 , C07D473/04 , C07D473/06 , C07D473/10 , C07D473/12
摘要： The present invention relates to substituted xanthines of general formula wherein R1 to R4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
摘要翻译： 本发明涉及通式为其中R1至R4如本文所定义的取代黄嘌呤，其互变异构体及其立体异构体，其混合物，其前体药物及其盐具有有价值的药理学性质，特别是对 酶二肽肽酶-IV（DPP-IV）。
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.065 秒)
